With the incredible breakthrough success of drugs now in our arsenal for slowing IPF disease progression, the increasing importance of identifying genetic mechanisms, closing the translational gap between preclinical and clinical results, and developing candidates to reverse fibrosis have opened up further challenges within IPF drug development.
Join “part 3” as the IPF community converges again to:
- Analyze the latest understanding of IPF pathology for improved target validation of next generation therapeutics and the potential to promote tissue regeneration to achieve reversal of fibrosis
- Critically discuss how to design the next generation of phase III clinical trials for candidate success in light of a current standard of care
- Outline progressions in the standardization of imaging and advancements of biomarkers to improve translational success and more confident diagnosis of patients